Re: Health-related Quality of Life of Patients With Locally Advanced or Metastatic Urothelial Cancer Treated With Enfortumab Vedotin After Platinum and PD-1/PD-L1 Inhibitor Therapy: Results From Cohort 1 of the Phase 2 EV-201 Clinical Trial Editorial Comment

被引：0
|
作者：
Chang, Sam S.
McGregor, B.
O'Donnell, P. H.
Balar, A.
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 210卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：218 / 218
页数：1
相关论文
共 50 条
  • [31] Health-related Quality of Life in Patients with moderate to advanced dry Age-related Macular Degeneration: Results from a Phase 1/2a clinical trial of CNTO 2476
    Pierson, Renee
    Orr, Susan C.
    Bogert, Jennifer
    Ho, Allen
    Malone, Terri
    Crosby, Ross
    Mathias, Susan
    Chang, Tom
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [32] TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
    Tagawa, Scott T.
    Petrylak, Daniel Peter
    Grivas, Petros
    Agarwal, Neeraj
    Sternberg, Cora N.
    Hernandez, Chris
    Siemon-Hryczyk, Peggy
    Goswami, Trishna
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
    Tagawa, Scott T.
    Petrylak, Daniel Peter
    Grivas, Petros
    Agarwal, Neeraj
    Sternberg, Cora N.
    Siemon-Hryczyk, Peggy
    Goswam, Trishna
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Phase 2 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Hsieh, James J.
    Rao, Arpit
    Pinto, Alvaro
    Bilen, Mehmet Asim
    Cohn, Allen Lee
    Di Simone, Christopher
    Shaffer, David R.
    Sarrio, Regina Girones
    Ribe, Sara Gunnestad
    Wu, Jane
    Schmidt, Emmett
    Kubiak, Peter
    Okpara, Chinyere
    Smith, Alan D.
    Young, Louise
    Motzer, Robert J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 133
  • [35] RESULTS OF A PHASE I TRIAL OF FT500, A FIRST-IN-CLASS, OFF-THE-SHELF, IPSC-DERIVED NK CELL THERAPY COMBINED WITH PD-1/PD-L1 CHECKPOINT BLOCKADE THERAPY AND IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Patel, Sandip
    Patel, Manish
    Gutierrez, Martin
    Anderson, Marlisa
    Szabo, Peter
    Valamehr, Bob
    Chu, Yu-Waye
    Beagle, Brandon
    Chou, Jeffrey
    Hong, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A787 - A787
  • [36] CLINICAL AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES FROM INTERVENTIONAL STUDIES IN FIRST-LINE (1L) ADVANCED OR METASTATIC UROTHELIAL CANCER (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Braun, N.
    Auti, P.
    Arca, E.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S19 - S19
  • [37] A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors
    Xu, Meiling
    Chen, Rongzheng
    Xing, Pengfei
    Kong, Yuehong
    Zhao, Xiangrong
    Zhang, Junjun
    Cai, Shang
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
    Brahmer, Julie R.
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Zhang, Jin
    Lubiniecki, Gregory M.
    Deitz, Anne C.
    Rangwala, Reshma
    Reck, Martin
    LANCET ONCOLOGY, 2017, 18 (12): : 1600 - 1609
  • [39] Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
    Osumi, H.
    Wakatsuki, T.
    Takahari, D.
    Ooki, A.
    Chin, K.
    Shoji, H.
    Ogura, M.
    Nakayama, I.
    Yamamoto, N.
    Hirano, H.
    Hara, H.
    Minashi, K.
    Shinozaki, E.
    Kato, K.
    Kurihara, N.
    Kitano, S.
    Takeuchi, K.
    Boku, N.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S875 - S876
  • [40] LATIFY: Phase 3 study of ceralasertib plus durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L) 1 and platinum-based therapy.
    Besse, Benjamin
    Castro, Gilberto
    Felip, Enriqueta
    Politi, Katerina A.
    Takahashi, Toshiaki
    Wang, Jie
    Dean, Emma
    Deans, Melissa
    Broadhurst, Helen
    Thiyagarajah, Piruntha
    Forde, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345